[1] |
Janunger KG, Hafstrm L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer[J]. Acta Oncol,2001,40(2-3):309-26.
|
[2] |
Rougier P, Lasser P, Ducreux M,et al. Preoperative chemotherapy of locally advanced gastric cancer[J]. AnnOncol, 1994, 5(Suppl 3): 59-68.
|
[3] |
He LF,Yang KH,Tian JH,et al. Meta analysis of clinical effectiveness of neoadjuvant chemotherapy for gastriccancer[J]. Ai Zheng, 2008, 27(4) : 407-12 .[ 贺岭风,杨克虎,田金徽,等. 胃癌新辅助化疗疗效的系统评价-Meta分析[J].癌症, 2008, 27( 4) : 407- 12.]
|
[4] |
Kosaka T, Ueshige N, Sugaya J, et al. Evaluation of intra-arterial infusion chemotherapy for advancedgastric cancer[J]. Gan To Kagaku Ryoho, 1998, 25(9): 1288-91.
|
[5] |
Greene FL.American Joint Committee on Cancer(AJCC).Cancer Staging Manual[M]. 6th.New York:Springer,2002.
|
[6] |
Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials[J]. BMJ, 2001, 323(7303):42-6.
|
[7] |
Ge LZ, Wu SG,Gong LP, et al. Treatment of Advanced Gastric Carcinoma by Gastric Artery InterventionChemoembolization Combined with Radical Cure Resection[J]. Zhong Liu Fang Zhi Yan Jiu,2007,34(4):300-2.[葛来增,吴仕光,龚立鹏,等.胃动脉介入化疗栓塞联合根治术治疗进展期胃癌[J]. 肿瘤防治研究, 2007, 34(4): 300-2.]
|
[8] |
Fu WJ, Xue YJ,Tang D, et al.Comparison of preoperative intra-arterial and intravenous chemotherapy in theresectable advanced gastric cancer[J]. Wu Jing Yi Xue Yuan Xue Bao, 2010, 19(1): 35-8.[傅文杰,薛彦俊,汤东,等.术前动脉介入化疗与全身化疗对进展期胃癌手术切除率的对比研究[J]. 武警医学院学报, 2010, 19(1): 35-8.]
|
[9] |
Ye ZB,Ma T, Xi WQ,et al. Clinical Study on Neoadjuvant Chemotherapy for Late Stage Gastric Carcinoma[J].Wai Ke Li Lun Yu Shi Jian, 2002, 7(5): 376-8.[叶正宝, 马韬,奚文崎,等. 晚期胃癌新辅助化疗的初步临床研究[J].外科理论与实践,2002,7(5): 376-8.]
|
[10] |
Bian YH, Cao H, Yu FR, et al. Effects of preoperative arterial infusion chemotherapy with oxaliplatin and5-Fu for patients with advanced gastric cancer[J].Zhongguo Pu Tong Wai Ke Za Zhi, 2009, 18(9): 955-9.[卞育海,曹晖, 郁丰荣, 等. 奥沙利铂联合5-Fu术前动脉化疗对进展期胃癌的临床疗效[J]. 中国普通外科杂志, 2009, 18(9): 955-9.]
|
[11] |
Ji XC, Wang WX, Yuan Y. Effect of preoperative arterial chemotherapy on resectable rate and radical rate ofthe patients with advanced gastric cancer[J].Xian Dai Shi Yong Yi Xue, 2005,17(7):403-4.[季晓春,汪闻夕,袁谊.术前动脉化疗对进展期胃癌手术切除率的影响[J]. 现代实用医学, 2005, 17(7): 403-4.]
|
[12] |
Li D, Wu PS. Comparative clinical study on preoperative intra-arterial infusion chemotherapy for advancedgastric cancer [J]. Zhongguo Ai Zheng Za Zhi, 2010, 20(4): 290-4.[李东,吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究[J].中国癌症杂志,2010,20(4): 290-4.]
|
[13] |
Yu FR, Cao H, Bian YH, et al. Effects of preoperative regional intra-arterial infusion chemotherapy forpatients with advanced gastric cancer [J].Wai Ke Li Lun Yu Shi Jian,2008, 13(1): 44-7.[郁丰荣,曹晖,卞育海,等.术前区域性动脉灌注化疗治疗进展期胃癌的临床研究[J].外科理论与实践, 2008, 13(1): 44-7.]
|
[14] |
Liu FK. The interventional therapy for advanced gastric cancer before and after operation[J]. ZhongguoShi Yong Wai Ke Za Zhi, 2001, 21(7): 403-4. [刘福坤.进展期胃癌手术前后介入治疗[J].中国实用外科杂志,2001,21(7):403-4.]
|
[15] |
Tokairin Y, Maruyama M, Baba H, et al. Pharmacokinetics of subselective arterial infusion chemotherapy[J]. Gan To Kagaku Ryoho, 2001, 28(11): 1795-8.
|
[16] |
Wu P, Zhu ZG, Ye ZB, et al. Experimental study on pharmacokinetics of floxuridine administeredpreoperatively via the left gastric artery[J]. Wai Ke Li Lun Yu Shi Jian, 2004, 9(2): 135-9.[吴鹏,朱正纲,叶正宝,等.5-氟尿嘧啶-2′-脱氧核苷经胃左动脉介入灌注后的药代动力学实验研究[J]. 外科理论与实践, 2004, 9(2): 135-9.]
|
[17] |
Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles[J]. Semin Oncol,2002, 29(2):119-25.
|
[18] |
Shchepotin I,Evans S,Chorny V,et al. Preoperative superselective intraarterial chemotherapy in the combinedtreatment of gastric-carcinoma [J]. Oncol Rep, 1995, 2(3): 473-9.
|
[19] |
Vanhoefer U, Rougier P, Wilke H,et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusionalfluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research andTreatment of Cancer Gastrointestinal Tract Cancer Cooperative Group[J]. J Clin Oncol,2000,18(14): 2648-57.
|
[20] |
Ross P, Nicolson M,Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, andprotracted venous-infusion fluorouracil(PVI 5-Fu) With epirubicin, cisplatin, and PVI 5-Fu in advancedesophagogastric cancer [J].J Clin Oncol,2002, 20(8): 1996-2004.
|
[21] |
Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluatingcapecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for thetreatment of advanced oesophago-gastric cancer [J]. Ann Oncol, 2009, 20(9): 1529-34.
|
[22] |
Takahashi I, Kakeji Y, Emi Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: currentstate and future prospects[J]. Gastric Cancer, 2003, 6(Suppl 1): 28-33.
|
[23] |
Van Cutsem E,Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plusfluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a reportof the V325 study group[J]. J Clin Oncol, 2006, 24(31): 4991-7.
|